Hereditary Dementia Trial Ready Cohort in Japan (HED-TRC)

PDRadiopharma Inc.0 个研究点目标入组 55 人开始时间: 待定最近更新: 2024年6月7日

试验速览

暂无简介。

•Provide written informed consent of their own free will from the patient or a representative.
•12 years or older at the time of informed consent.
•Have a study partner that is willing to participate as a source of information and has approximately weekly contact with the participant (contact can be in-person, via telephone or electronic communication).
•Approximately healthy without severe current or past medical history which hinder research participation.
•Have sufficient eyesight and hearing to undergo neuropsychological examinations.
•Have sufficient Japanese ability.

•History within 3 months of psychosis, agitation, or behavior problem which interfere study protocol.
•Have a history of alcohol or substance use disorder defined by DSM-V within 2 years.
•In the unstable medical condition judged by the investigator that pose risks or that interfere research result or subject's performance. It includes uncontrolled hypertension, uncontrolled diabetes, clinically serious heart, lung, kidney, liver, endocrine, or systemic disease.
•History of primary or recurrent malignant cancer within the past 3 years, except for non-melanoma skin cancer, removed squamous cell carcinoma, basal cell carcinoma, cervical intraepithelial neoplasia, or non-invasive prostate cancer with normal PSA after treatment.
•With an ineligibility judged by the principal investigator.

MMSE, Cognitive function score by CDR-SB

未报告次要终点

发起方